Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;130(9):667-683.
doi: 10.1002/cncy.22603. Epub 2022 Jun 2.

Insights on recent innovations in bladder cancer immunotherapy

Mohamed A Abd El-Salam  1   2   3   4 , Claire E P Smith  2   5 , Chong-Xian Pan  1   2
Affiliations
Free article
Review

Insights on recent innovations in bladder cancer immunotherapy

Mohamed A Abd El-Salam et al. Cancer Cytopathol. 2022 Sep.
Free article

Abstract

Bladder carcinoma is the most common genitourinary cancer, with a high prevalence and global incidence. In addition to early detection by cytology, the management of bladder cancer has recently advanced, not only by improvements in conventional treatments such as surgery and chemotherapy, but also through the introduction of immunotherapeutic strategies. The number of approved immunotherapeutic agents has dramatically increased, with various preclinical and clinical applications in cancer drug discovery. Some bladder cancer immunotherapies include immune checkpoint inhibitors, adoptive cell therapy, cytokine-based therapy, bispecific antibodies, and antibody-drug conjugates. This review provides an overview of some of the innovative immunotherapeutic agents approved and in development that can potentially be used in the treatment of bladder cancer.

Keywords: adoptive cell therapy; antibody-drug conjugate; bi-specific antibodies; bladder cancer; cytokine-based therapy; immune checkpoint inhibitor; immunotherapy; oncolytic virus.

PubMed Disclaimer

References

REFERENCES

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33.
    1. Sullivan PS, Chan JB, Levin MR, Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res. 2010;2(4):412-440.
    1. VandenBussche CJ. A review of the Paris system for reporting urinary cytology. Cytopathology. 2016;27(3):153-156.
    1. Rosenthal DL, Wojcik EM, Kurtycz DF. The Paris system for reporting urinary cytology. Cham, Switzerland: Springer; 2022.
    1. Siddiqui MT, Fadda G, Han JH, et al. High grade urothelial carcinoma (HGUC). In: Wojcik EM, Rosenthal DL, eds. The Paris system for reporting urinary cytology. 2nd ed: Springer; 2022:97-114.

MeSH terms

LinkOut - more resources